Emerging research on oral therapeutics for vitiligo. Recently, at the european academy of dermatology and venereology (eadv) congress in 2023, incyte announced the results of their phase 2 trial.
Vitiligo management encompasses various aspects, including autoimmune factors, treatment options, support groups, stress management, and diagnostic. Dr viktoria eleftheriadou discusses recent progress and the future trajectory of vitiligo treatment, including the approval of ruxolitinib.
Ruxolitinib Is The First Approved In Vitiligo Therapy.
Emerging research on oral therapeutics for vitiligo.
The Economic Burden Was Markedly Higher For Patients Receiving Treatment With Systemic Effects Or With New Mental Health Diagnoses Than For The Total Vitiligo.
Vitiligo is a condition that causes your skin to lose its colour or pigment.
Images References :
A Supplemental New Drug Application For Ruxolitinib Cream In Vitiligo Is Currently Under Priority Review By The Fda, With A Prescription Drug User Fee Act Target.
“depending on the extent, stability, and location of vitiligo, treatment can range from topical creams and nutritional changes to phototherapy and systemic.
Jun 24, 2024 12:56 Ist.
The economic burden was markedly higher for patients receiving treatment with systemic effects or with new mental health diagnoses than for the total vitiligo.